JP2024506667A - 多置換シロシビン誘導体およびその使用方法 - Google Patents

多置換シロシビン誘導体およびその使用方法 Download PDF

Info

Publication number
JP2024506667A
JP2024506667A JP2023548816A JP2023548816A JP2024506667A JP 2024506667 A JP2024506667 A JP 2024506667A JP 2023548816 A JP2023548816 A JP 2023548816A JP 2023548816 A JP2023548816 A JP 2023548816A JP 2024506667 A JP2024506667 A JP 2024506667A
Authority
JP
Japan
Prior art keywords
group
nucleic acid
acid sequence
compound
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023548816A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506667A5 (enExample
Inventor
エム． ハーゲル，ジリアン
ジェイ． ファッチーニ，ピーター
リン，チャン－チュン
Original Assignee
エンベリック バイオサイエンシズ カナダ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エンベリック バイオサイエンシズ カナダ インコーポレイテッド filed Critical エンベリック バイオサイエンシズ カナダ インコーポレイテッド
Publication of JP2024506667A publication Critical patent/JP2024506667A/ja
Publication of JP2024506667A5 publication Critical patent/JP2024506667A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/10—Nitrogen as only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
    • C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/0102—Diaminopimelate decarboxylase (4.1.1.20)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01028—Aromatic-L-amino-acid decarboxylase (4.1.1.28), i.e. tryptophane-decarboxylase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y402/00—Carbon-oxygen lyases (4.2)
    • C12Y402/01—Hydro-lyases (4.2.1)
    • C12Y402/0102—Tryptophan synthase (4.2.1.20)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2023548816A 2021-02-12 2022-02-11 多置換シロシビン誘導体およびその使用方法 Pending JP2024506667A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163149001P 2021-02-12 2021-02-12
US63/149,001 2021-02-12
US202163247881P 2021-09-24 2021-09-24
US63/247,881 2021-09-24
PCT/CA2022/050206 WO2022170438A1 (en) 2021-02-12 2022-02-11 Multi-substituent psilocybin derivatives and methods of using

Publications (2)

Publication Number Publication Date
JP2024506667A true JP2024506667A (ja) 2024-02-14
JP2024506667A5 JP2024506667A5 (enExample) 2025-02-19

Family

ID=82838865

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023548816A Pending JP2024506667A (ja) 2021-02-12 2022-02-11 多置換シロシビン誘導体およびその使用方法

Country Status (9)

Country Link
US (4) US11918594B2 (enExample)
EP (1) EP4291549A4 (enExample)
JP (1) JP2024506667A (enExample)
KR (1) KR20230157342A (enExample)
AU (1) AU2022218921A1 (enExample)
CA (1) CA3208152A1 (enExample)
IL (1) IL305125A (enExample)
MX (1) MX2023009491A (enExample)
WO (1) WO2022170438A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11312684B1 (en) 2021-02-10 2022-04-26 Eleusis Therapeutics Us, Inc. Pharmaceutically acceptable salts of psilocin and uses thereof
CA3219577A1 (en) * 2021-05-27 2022-12-01 Nicholas Stuart William MILNE Methods for producing tryptamine derivatives.
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
GB202315025D0 (en) * 2023-09-29 2023-11-15 Psylink Uab Production and medical use of psilocybin and related compounds
WO2025099444A1 (en) * 2023-11-09 2025-05-15 Beckley Psytech Limited N-Acetylserotonin (NAS) Analogues

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3182071A (en) * 1961-06-27 1965-05-04 Warner Lambert Pharmaceutical Acylated indole derivatives
US4803218A (en) * 1982-09-29 1989-02-07 Mcneilab, Inc. 3-aminoalkyl-1H-indole-5-urea and amide derivatives
JP2004532209A (ja) * 2001-03-29 2004-10-21 イーライ・リリー・アンド・カンパニー ５−ｈｔ６受容体の拮抗薬としてのｎ−（２−アリールエチル）ベンジルアミン
EP1826267A1 (en) * 2006-02-22 2007-08-29 Combinature Biopharm AG Novel halogenases
WO2016134145A2 (en) * 2015-02-19 2016-08-25 University Of Florida Research Foundation, Inc. Artificial self-sufficient cytochrome p450s
KR20180103379A (ko) * 2017-03-09 2018-09-19 고려대학교 산학협력단 플라빈-의존형 할로게나아제 및 이를 이용한 할로겐화 인돌 화합물의 제조방법
WO2019183358A2 (en) * 2018-03-21 2019-09-26 University Of Florida Research Foundation, Incorporated Whole cell processes to produce nitroaromatics
WO2020181194A1 (en) * 2019-03-07 2020-09-10 University Of Padova Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
JP2023524598A (ja) * 2020-05-08 2023-06-12 サイレラ インコーポレイテッド 新規な組成物および医薬組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022047583A1 (en) * 2020-09-02 2022-03-10 Magicmed Industries Inc. Nitrated psilocybin derivatives and use thereof for modulating 5-ht2a receptor and for treating a psychiatric disorder
WO2022115944A1 (en) * 2020-12-01 2022-06-09 Magicmed Industries Inc. Carboxylated psilocybin derivatives and methods of using

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3182071A (en) * 1961-06-27 1965-05-04 Warner Lambert Pharmaceutical Acylated indole derivatives
US4803218A (en) * 1982-09-29 1989-02-07 Mcneilab, Inc. 3-aminoalkyl-1H-indole-5-urea and amide derivatives
JP2004532209A (ja) * 2001-03-29 2004-10-21 イーライ・リリー・アンド・カンパニー ５−ｈｔ６受容体の拮抗薬としてのｎ−（２−アリールエチル）ベンジルアミン
EP1826267A1 (en) * 2006-02-22 2007-08-29 Combinature Biopharm AG Novel halogenases
WO2016134145A2 (en) * 2015-02-19 2016-08-25 University Of Florida Research Foundation, Inc. Artificial self-sufficient cytochrome p450s
KR20180103379A (ko) * 2017-03-09 2018-09-19 고려대학교 산학협력단 플라빈-의존형 할로게나아제 및 이를 이용한 할로겐화 인돌 화합물의 제조방법
WO2019183358A2 (en) * 2018-03-21 2019-09-26 University Of Florida Research Foundation, Incorporated Whole cell processes to produce nitroaromatics
WO2020181194A1 (en) * 2019-03-07 2020-09-10 University Of Padova Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
JP2023524598A (ja) * 2020-05-08 2023-06-12 サイレラ インコーポレイテッド 新規な組成物および医薬組成物

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
ANIKA KREMER ET AL., APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, vol. 79, no. 6, JPN6025048241, July 2008 (2008-07-01), pages 951 - 961, ISSN: 0005738272 *
BINURAJ R. K. MENON ET AL., ORGANIC & BIOMOLECULAR CHEMISTRY, vol. 14, no. 39, JPN6025048244, 2016, pages 9354 - 9361, ISSN: 0005738275 *
FUMIO YAMADA ET AL., CHEMICAL AND PHARMACEUTICAL BULLETIN, vol. 50, no. 1, JPN6025048240, 2002, pages 92 - 99, ISSN: 0005738270 *
J． PRATUANGDEJKUL ET AL., CURRENT MEDICINAL CHEMISTRY, vol. 12, no. 20, JPN7025005063, 1 September 2005 (2005-09-01), pages 2393 - 2410, ISSN: 0005738277 *
JEFFREY D. RUDOLF ET AL., JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 135, no. 5, JPN6025048242, 28 January 2013 (2013-01-28), pages 1895 - 1902, ISSN: 0005738273 *
JULIA WINKELBLECH ET AL., ORGANIC & BIOMOLECULAR CHEMISTRY, vol. 14, no. 41, JPN7025005062, 2016, pages 9883 - 9895, ISSN: 0005738276 *
MARCEL FRESE ET AL., CHEMCATCHEM, vol. 6, no. 5, JPN6025048243, 13 February 2014 (2014-02-13), pages 1270 - 1276, ISSN: 0005738274 *
MAXIMILIAN VON STRANDTMANN ET AL., JOURNAL OF MEDICINAL CHEMISTRY, vol. 8, no. 2, JPN6025048245, March 1965 (1965-03-01), pages 200 - 204, ISSN: 0005738278 *
NICOLA STEFFAN ET AL., CHEMBIOCHEM, vol. 8, no. 11, JPN7025005064, 10 July 2007 (2007-07-10), pages 1298 - 1307, ISSN: 0005738279 *
R． A. ABRAMOVITCH, JOURNAL OF THE CHEMICAL SOCIETY, JPN7025005066, 1956, pages 4593 - 4602, ISSN: 0005738271 *
XIA YU ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 287, no. 2, JPN7025005065, January 2012 (2012-01-01), pages 1371 - 1380, ISSN: 0005738280 *

Also Published As

Publication number Publication date
KR20230157342A (ko) 2023-11-16
AU2022218921A9 (en) 2024-01-11
WO2022170438A1 (en) 2022-08-18
US12133856B2 (en) 2024-11-05
US20250025483A1 (en) 2025-01-23
IL305125A (en) 2023-10-01
MX2023009491A (es) 2023-10-13
CA3208152A1 (en) 2022-08-18
US11918594B2 (en) 2024-03-05
US20230270768A1 (en) 2023-08-31
US20240122950A1 (en) 2024-04-18
US20240173340A1 (en) 2024-05-30
EP4291549A1 (en) 2023-12-20
US12128058B2 (en) 2024-10-29
AU2022218921A1 (en) 2023-09-21
EP4291549A4 (en) 2025-01-22

Similar Documents

Publication Publication Date Title
JP2024506667A (ja) 多置換シロシビン誘導体およびその使用方法
US11931338B2 (en) Nitrilated psilocybin derivatives and methods of using
US11998557B2 (en) Halogenated psilocybin derivatives and methods of using
US11891360B2 (en) Glycosylated psilocybin derivatives and methods of using
US20230043896A1 (en) Hydroxylated psilocybin derivatives and methods of using
US11891359B2 (en) Prenylated psilocybin derivatives and methods of using
US12605361B2 (en) Carboxylated psilocybin derivatives and methods of using
CA3191095A1 (en) Nitrated psilocybin derivatives and use thereof for modulating 5-ht2a receptor and for treating a psychiatric disorder
US20260103442A1 (en) Aminated psilocybin derivatives and methods of using
CN110438101A (zh) 一种异黄酮O-甲基转移酶GmIOMT3及编码基因及应用
WO2023102659A1 (en) Glycosylated isopropylamine mescaline derivatives and methods of using
WO2023102658A1 (en) Glycosylated mescaline derivatives and methods of using
Zeringo Biochemical and structural studies of the circadian enzymes CLOCK and casein kinase 1, and indolotryptoline biosynthetic enzymes

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251125

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260407